Health News, AI-Analyzed

The latest Health stories — decoded across 19 dimensions.

Germany records over 5,000 heat-related deaths in June heat wave

The Robert Koch Institute estimated that 5,120 people in Germany died from heat from the start of this summer through June 28, surpassing the recent annual average of about 2,900 heat-related deaths from 2023–2025. The institute said 4,310 of those deaths occurred in the week of June 22–28, when parts of the country exceeded 40°C and some stations recorded above 41°C. Older people were hardest hit, with about 2,950 deaths among those aged 85 and older. The finding draws on monitored death records and weather service data and highlights an acute strain on public health during extreme heat.

2 min read

Johnson & Johnson receives FDA approval for dual energy ablation catheter

Johnson & Johnson won U.S. FDA approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform, an ablation catheter that can deliver both radiofrequency and pulsed field energy through a single device and is integrated with the CARTO mapping ecosystem. U.S. procedures are set to start after a phased commercial rollout this summer. The approval is an early example of management’s roadmap to introduce pulsed field ablation tools, following cardiovascular medtech sales of almost US$9.0 billion in 2025, and may test how MedTech innovation can offset pricing, tariff, and patent headwinds while leaving near-term pharma and litigation risks unchanged.

3 min read

Toronto centre launches trial testing blood for residual cancer

Princess Margaret Cancer Centre researchers, led by Dr. Lillian Siu, have launched the SHERLOCK trial to enroll 7,000 patients who finished radiation, chemotherapy or other treatments and test their blood for tiny amounts of tumour DNA, known as molecular residual disease. If liquid biopsies are positive, patients could receive additional experimental treatments such as immunotherapies; if negative, further chemo or radiation might be stopped to avoid side effects. The observational trial will follow patients for at least five years, aims to compare results across cancer types, and is funded by a $50-million donation.

5 min read

Health workers strike disrupts Ebola response in Congo

Health workers at the epicenter of Congo's Ebola outbreak have walked off the job in Ituri province to protest delayed wages and bonuses and limited protective gear, officials and workers said. The outbreak, declared on May 15, has recorded 1,708 cases and 580 deaths, and authorities say the first month was the worst on record. The walkout threatens response efforts as some treatment centers approach full capacity and enrollment begins for clinical trials of treatments for the Bundibugyo virus, while WHO warns the virus is spreading amid population movement and insecurity.

2 min read

FDA grants accelerated approval to TRUTAKNA for IgA nephropathy

The U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for progression. Approval was based on a prespecified 36-week interim analysis of the global ORIGIN 3 Phase 3 trial, in which TRUTAKNA produced a 46% reduction from baseline in UPCR and a 42% reduction versus placebo (p<0.0001). TRUTAKNA was generally well tolerated, with infections and local administration reactions as the most common adverse events. Continued approval may require verification of long-term kidney function benefit in the ongoing eGFR analysis, expected Q3 2026.

12 min read

Alamar launches commercial eMTBR-Tau blood immunoassay

Alamar Biosciences on July 7, 2026 launched the first commercial eMTBR-Tau immunoassay, the company said in a Globe Newswire release. The assay is included in NULISAseq Neuro 220 multiplexed panel kits, is immediately deployable on the installed base of ARGO HT instruments, and is available as a single-plex through Alamar's Technology Access Program (TAP). eMTBR-Tau is a plasma biomarker that reflects tau tangle pathology and has shown strong associations with cognitive decline, clinical disease staging and therapeutic response monitoring in Alzheimer's disease, potentially enabling more precise patient staging and trial monitoring.

1 min read

European anti-fraud office uncovers counterfeit condom trafficking route

The European anti-fraud office uncovered a trafficking route that distributed more than 200,000 counterfeit condoms originating from China and falsely declared as toys to bypass European Union quality rules. The products did not undergo required medical device checks for microbial contamination, biocompatibility, leaks, dimensions, shelf life or stability, creating risks of sexually transmitted infections, unplanned pregnancies and exposure to unsafe chemicals. Authorities seized fake condoms worth over €200,000 in Romania, Serbia and Spain, and the agency, working with Chinese authorities, identified the exporter but withheld the identity and brand details.

2 min read

European Commission approves epcoritamab with lenalidomide and rituximab for follicular lymphoma

The European Commission granted marketing authorization for epcoritamab (Tepkinly) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma, based on Phase 3 EPCORE FL-1 data. In the randomized trial (n=243 combination, n=245 control) the combination reduced risk of progression or death by 79% (HR 0.21), produced a 96% overall response rate and 74% complete response rate versus 81% ORR and 43% CR with lenalidomide and rituximab alone. The approval establishes a chemotherapy-free, bispecific-based second-line option in Europe while safety signals included serious adverse reactions in 44% of combination-treated patients.

16 min read

Novartis to acquire Myricx Bio for up to $1.5bn

Novartis has signed an agreement to acquire Myricx Bio in a transaction valued at up to $1.5 billion, comprising a $1.1 billion upfront payment and up to $400 million in milestone payments. Myricx develops antibody-drug conjugates using N-myristoyltransferase inhibitor (NMTi) payloads, which in preclinical data may be active across solid tumours and against tumours resistant to topoisomerase 1 inhibitors. Novartis says the platform could broaden ADC use across multiple tumour settings, and the company expects the deal to close in the second half of 2026 pending regulatory approvals and customary closing conditions.

2 min read

WHO member states restart talks to finalize pandemic treaty annex

WHO member states began another session at the agency’s Geneva headquarters to finalize the missing Pathogen Access and Benefit-Sharing (PABS) annex of the pandemic treaty adopted in May 2025. Wealthy and developing countries remain divided over how the system will operate, and negotiators have made slow, incremental progress across six previous rounds. WHO director-general Tedros urged continued effort as an Ebola outbreak in the Democratic Republic of Congo — with 1,528 confirmed cases and 492 confirmed deaths, and spillover into Uganda — and a recent hantavirus incident underscore persistent global risks. Only once the annex is complete can countries begin ratifying the treaty.

3 min read

Novartis agrees to buy Myricx Bio for up to $1.5 billion

Novartis has agreed to acquire U.K.-based Myricx Bio for up to $1.5 billion, with $1.1 billion paid upfront and up to $400 million in milestone payments, in a deal expected to close in the second half of 2026. Myricx develops antibody-drug conjugates (ADCs) for cancer treatment, and Novartis said the acquisition supports its strategy to scale innovative platforms and to pursue new payload mechanisms to overcome ADC resistance. The purchase reinforces Novartis's focus on oncology platform building and could accelerate development of new ADC payloads within its pipeline.

1 min read

Cholera, measles and food shortages threaten 200,000 in Sudan

Sudan Doctors Network warns that more than 200,000 people, including over 20,000 children, face severe humanitarian and public health threats in western Bara, North Kordofan, amid measles and cholera outbreaks and acute shortages of food and medicine. The group reported more than 100 measles cases among children at Bara health centers and 45 cholera cases, while two hospitals operate without medical supplies. Sudan's health ministry has recorded 911 cholera cases and 127 deaths in North and West Kordofan, and the network appealed to the UN and relief agencies for urgent deliveries to prevent rising mortality.

2 min read

Punjab registers 94.3 million digital health profiles

Punjab's government has compiled health and demographic profiles for about 94.3 million residents in its first digital health census, assigning unique identification numbers to every household and registering data through 14,300 community health inspectors' door-to-door visits. The dashboard holds information on health status, lifestyle, economic conditions, drinking water access and disabilities, and officials say services and medicine supply will be planned on verified digital data. The chief minister ordered a population management campaign, faster activation of cath labs (16 planned, five functioning), a proposal to link citizens to primary care and a disaster recovery site for the health database.

3 min read

Double earthquakes strike La Guaira and overwhelm local hospitals

Two earthquakes of magnitude 7.2 and 7.5 hit La Guaira state, Venezuela, causing widespread destruction, scores of collapsed buildings and more than 2,600 deaths, according to official figures. Hospitals were overwhelmed within hours and more than 12,600 people were injured, prompting volunteers and medical teams to set up makeshift clinics in sites such as a McDonald's and a bus terminal where thousands have received care. Medical teams report diarrheal and dysentery cases and the UN warns that overcrowded shelters increase the risk of epidemics, while emergency responders continue search, rescue and basic treatment operations.

3 min read